logo
Plus   Neg
Share
Email

Bayer Files Riociguat For Regulatory Approval In Japan To Treat PAH

Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said Wednesday that it has filed riociguat for the treatment of pulmonary arterial hypertension or PAH for regulatory approval in Japan.

The submission of riociguat in PAH in Japan is based on results from the randomized, double-blind, placebo-controlled, global Phase III study PATENT-1 as well as long-term data from PATENT-2 available at the time. These assessed the efficacy and safety of oral riociguat in the treatment of PAH. The PATENT-1 study met its primary endpoint by demonstrating a statistically significant improvement (p<0.0001) from baseline in the six-minute walk test (6MWT), a marker of disease severity and predictor of survival, after 12 weeks compared with placebo.

PAH is a progressive and life-threatening form of pulmonary hypertension in which the blood pressure in the pulmonary arteries is significantly increased due to vasoconstriction and which can lead to heart failure and death.

In January 2014, the MHLW in Japan had approved riociguat under the trade name Adempas in another life-threatening form of pulmonary hypertension, namely chronic thromboembolic pulmonary hypertension or CTEPH.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT